Selected article for: "care point and community transmission"

Author: Mercer, Tim R.; Salit, Marc
Title: Testing at scale during the COVID-19 pandemic
  • Cord-id: dp9loyeu
  • Document date: 2021_5_4
  • ID: dp9loyeu
    Snippet: Assembly and publication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome in January 2020 enabled the immediate development of tests to detect the new virus. This began the largest global testing programme in history, in which hundreds of millions of individuals have been tested to date. The unprecedented scale of testing has driven innovation in the strategies, technologies and concepts that govern testing in public health. This Review describes the changing role of te
    Document: Assembly and publication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome in January 2020 enabled the immediate development of tests to detect the new virus. This began the largest global testing programme in history, in which hundreds of millions of individuals have been tested to date. The unprecedented scale of testing has driven innovation in the strategies, technologies and concepts that govern testing in public health. This Review describes the changing role of testing during the COVID-19 pandemic, including the use of genomic surveillance to track SARS-CoV-2 transmission around the world, the use of contact tracing to contain disease outbreaks and testing for the presence of the virus circulating in the environment. Despite these efforts, widespread community transmission has become entrenched in many countries and has required the testing of populations to identify and isolate infected individuals, many of whom are asymptomatic. The diagnostic and epidemiological principles that underpin such population-scale testing are also considered, as are the high-throughput and point-of-care technologies that make testing feasible on a massive scale.

    Search related documents:
    Co phrase search for related documents
    • academic commercial and acute respiratory syndrome: 1, 2, 3, 4, 5
    • acid amplification and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acid amplification and additional round: 1
    • acid antigen testing and acute respiratory syndrome: 1, 2, 3, 4
    • acute respiratory syndrome and additional mutation: 1, 2, 3
    • acute respiratory syndrome and additional round: 1, 2, 3
    • acute respiratory syndrome and additional variant: 1, 2, 3, 4, 5, 6, 7, 8, 9